O
n Friday, the Food and Drug Administration approved the first-ever drug to rely on a Nobel-prize-winning technique that mutes disease-causing genes — a watershed moment for that field of research, and a starting pistol for the race to find a way to use the therapy for other debilitating genetic diseases like ALS or Huntington’s.
But already, a major question looms: What if the technique won’t work in other parts of the body?
Unlock this article by subscribing to STAT Plus. Try it FREE for 30 days!
SUBSCRIBE TODAYWhat is it?
STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.
What's included?
- Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
- Subscriber-only networking events and panel discussions across the country
- Monthly subscriber-only live chats with our reporters and experts in the field
- Discounted tickets to industry events and early-bird access to industry reports
About the Author
